CHRYSTAL KILLINGER: Open Payments
NPI 1609267731 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,978 in 102 payments from 15 companies in 2025. Trend: 2023 $1,799 · 2024 $1,770 · 2025 $1,978
Food & beverage: $1,978
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $583 |
| Janssen Biotech, Inc. | 14 | $278 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $248 |
| Gilead Sciences, Inc. | 8 | $172 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $143 |
| Lilly USA, LLC | 4 | $98 |
| Ipsen Biopharmaceuticals, Inc | 4 | $89 |
| Madrigal Pharmaceuticals | 4 | $73 |
| Regeneron Healthcare Solutions, Inc. | 3 | $72 |
| Intercept Pharmaceuticals, Inc. | 4 | $72 |
Products named: RINVOQ, TREMFYA, ENTYVIO, DUPIXENT, XIFAXAN, EOHILIA, SKYRIZI, LINZESS.
Industry payments across MO — which companies pay providers there.
